Clinical Trial: A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Brief Summary: Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.

Detailed Summary:

The aim of this study is to determine whether dalfampridine can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.

The objective of this double masked crossover study is to determine whether visual function can be improved in numerous parameters. This includes high contrast visual acuity, low contrast visual acuity, visual field, visual quality of life (VFQ-39), electrophysiology, multi focal electro retinography (mERG), visual evoked potential (VEP), and structure, spectral domain optical coherence tomography (OCT).

Based on the promising results of the use of dalfampridine in Multiple Sclerosis (MS) and in stroke, we hypothesize that the patients with chronic stable deficits after nonarteritic ischemic optic neuropathy (NAION) will have improved visual function with the administration of dalfampridine.

Sponsor: Neuro-Ophthalmologic Associates, PC

Current Primary Outcome: Improve visual function [ Time Frame: two weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Neuro-Ophthalmologic Associates, PC

Dates:
Date Received: July 26, 2013
Date Started: July 2013
Date Completion:
Last Updated: January 22, 2016
Last Verified: October 2015